Tailored for incidental findings on chest radiographs, the qXR for Lung Nodule (qXR-LN) software utilizes artificial intelligence (AI) to help detect suspected pulmonary nodules ranging between 6 to 30 mm.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the artificial intelligence (AI)-enabled qXR for Lung Nodule (qXR-LN) software, which may enhance detection of pulmonary nodules on chest X-rays.
Qure.ai, the developer of the software, said qXR-LN detects and highlights regions of suspected pulmonary nodules, ranging between 6 to 30 mm in size. Geared to diagnosing incidental findings on chest radiographs, the AI software can also be utilized as a second reader in the review of AP and PA chest radiographs, according to Qure.ai.
The company noted that one multicenter study, involving 40 sites, revealed a 94 percent AUC for qXR-LN in stand-alone detection of lung nodule detection.
“Solutions like Qure.ai's qXR-LN are a significant step towards establishing new possibilities in pulmonary imaging, particularly within oncology. The need for early-stage lung cancer detection is crucial, and tools like qXR-LN can play a significant role in the early detection of incidental nodules,” noted Vishisht Mehta, M.D., F.C.C.P., the Director of Interventional Pulmonology at the Lung Center of Nevada in Las Vegas.
AMA Issues 2025 Category III CPT Code for the ECG-Based AI Platform EchoGo Heart Failure
July 2nd 2024The EchoGo Heart Failure platform is reportedly the only AI-powered technology to receive a CPT reimbursement code for echocardiography detection of heart failure with preserved ejection fraction.
New Study Shows Non-Radiologists Interpreting 28 Percent of Imaging for Medicare Patients
June 28th 2024While radiologists interpreted approximately 99 percent of all non-cardiac CT, MRI and nuclear medicine studies in hospital and emergency department settings for Medicare beneficiaries, new research shows significantly less radiologist review of cardiac imaging and office-based imaging.